Compare Abeona Therapeutics Inc (ABEO) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs TransMedics Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while TransMedics Group Inc trades at $70.34 (market cap $2.46B). The key difference: TransMedics Group Inc is far larger — about 6.6× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | TMDX | |
|---|---|---|
Market Cap | $373.32M | $2.46B |
Sector | Health | Technology |
52-Week High | $7.23 | $150.42 |
52-Week Low | $4.17 | $61.99 |
Enterprise Value | $228.22M | $2.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TMDX trades at $71.23, up 3.44% on the day, but technical indicators signal a bearish trend. The company reported strong profitability with a 27.04% net income margin and 45.22% ROE for 2025, though Q1 2026 earnings missed expectations. Recent strategic investments in European organ logistics aim to expand its competitive moat, but margin pressure from expansion costs is a key concern noted by analysts (Zacks Investment Research, 2026-07-07).
The investment outlook is mixed: strong analyst consensus (75% buy ratings) and a $108.71 price target suggest significant upside, but near-term execution risks and bearish technicals warrant caution. Long-term growth drivers in transplant logistics are compelling, yet investors must weigh expansion costs against the potential for market share gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
